EAAT3 may be effective in the treatment of advanced renal cell carcinoma by regulating the mTOR pathway as effectively as temsirolimus and everolimus, which are kinase inhibitors of mTOR complex 1 (mTORC1) [29]. The gene discussed is SLC1A1; the disease is renal cell carcinoma.